Cytomegalovirus-vectored vaccines for HIV and other pathogens. (1st March 2020)

• Record Type: Journal Article
• Authors: Barry, Peter A.; Deere, Jesse D.; Yue, Yujuan; Chang, William W.L.; Schmidt, Kimberli A.; Wussow, Felix; Chiuppesi, Flavia; Diamond, Don J.; Sparger, Ellen E.; Walter, Mark R.; Hartigan-O'Connor, Dennis J.
• Is Part Of: AIDS. Volume 34:Number 3(2020)
• Publication Date: 2020-03-01
• Subjects: AIDS -- cytomegalovirus -- cytomegalovirus vaccine vector -- HIV -- nonhuman primate -- monkey model -- rhesus -- rhesus cytomegalovirus -- simian immunodeficiency virus -- unconventional T-cell responses; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000002396
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : N/A: The use of cytomegalovirus (CMV) as a vaccine vector to express antigens against multiple infectious diseases, including simian immunodeficiency virus, Ebola virus, plasmodium, and mycobacterium tuberculosis, in rhesus macaques has generated extraordinary levels of protective immunity against subsequent pathogenic challenge. Moreover, the mechanisms of immune protection have altered paradigms about viral vector-mediated immunity against ectopically expressed vaccine antigens. Further optimization of CMV-vectored vaccines, particularly as this approach moves to human clinical trials will be augmented by a more complete understanding of how CMV engenders mechanisms of immune protection. This review summarizes the particulars of the specific CMV vaccine vector that has been used to date (rhesus CMV strain 68-1) in relation to CMV natural history.